Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure (GENETIC-AF)
- Pincipal Investigator: Soraya Samii, M.D., Ph.D.
- Nurse Coordinator: Katie Loffredo, R.N. 717-531-6855
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) (EMANATE)
A Phase 3, Single-Blind Study to Evaluate the Effect of GS-6615 on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT-3 Syndrome
This study will evaluate the effect of GS-6615 on shortening of the corrected QT interval (QTc), safety, and tolerability in adults with type 3 long QT syndrome (LQT3). During the single-blind treatment period (24 weeks), participants will receive GS-6615 and/or placebo to match GS-6615. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving GS-6615 during an open-label extension phase.